KRAS and colorectal carcinoma: In this context, the authors describe a 60% inhibition of CRC incidence in mice with activated Kras mutation by supplementing 150 or 300 ppm resveratrol (which in humans would correspond to a dose of 105 and 210 mg) for nine weeks [59].